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Abstract
Five species of Ebola virus (EBOV) have been identified, with nucleotide differences of 30–45% between species. Four of
these species have been shown to cause Ebola hemorrhagic fever (EHF) in humans and a fifth species (Reston ebolavirus)i s
capable of causing a similar disease in non-human primates. While examining potential serologic cross-reactivity between
EBOV species is important for diagnostic assays as well as putative vaccines, the nature of cross-reactive antibodies
following EBOV infection has not been thoroughly characterized. In order to examine cross-reactivity of human serologic
responses to EBOV, we developed antigen preparations for all five EBOV species, and compared serologic responses by IgM
capture and IgG enzyme-linked immunosorbent assay (ELISA) in groups of convalescent diagnostic sera from outbreaks in
Kikwit, Democratic Republic of Congo (n=24), Gulu, Uganda (n=20), Bundibugyo, Uganda (n=33), and the Philippines
(n=18), which represent outbreaks due to four different EBOV species. For groups of samples from Kikwit, Gulu, and
Bundibugyo, some limited IgM cross-reactivity was noted between heterologous sera-antigen pairs, however, IgM
responses were largely stronger against autologous antigen. In some instances IgG responses were higher to autologous
antigen than heterologous antigen, however, in contrast to IgM responses, we observed strong cross-reactive IgG antibody
responses to heterologous antigens among all sets of samples. Finally, we examined autologous IgM and IgG antibody
levels, relative to time following EHF onset, and observed early peaking and declining IgM antibody levels (by 80 days) and
early development and persistence of IgG antibodies among all samples, implying a consistent pattern of antibody kinetics,
regardless of EBOV species. Our findings demonstrate limited cross-reactivity of IgM antibodies to EBOV, however, the
stronger tendency for cross-reactive IgG antibody responses can largely circumvent limitations in the utility of heterologous
antigen for diagnostic assays and may assist in the development of antibody-mediated vaccines to EBOV.
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Introduction
The genus Ebolavirus, family Filoviridae, has five identified
(including one proposed) viral species [1]. Of these, four viral
species, Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Co ˆte
d’Ivoire ebolavirus (CIEBOV), and Bundibugyo ebolavirus (BEBOV)
are known to cause Ebola hemorrhagic fever (EHF) in humans,
and in previous large outbreaks due to ZEBOV, SEBOV, and
BEBOV, case fatality has ranged from 32 to 90% [2,3,4,5,6,7,8,9].
A fifth viral species, Reston ebolavirus (REBOV), has been shown
to cause severe disease in non-human primates [10,11,12] and
can infect swine [13]. Similarly, evidence of human infections
with REBOV have been documented serologically, however, no
human disease has been associated with REBOV [13,14,15].
Despite the common characteristic of severe pathogenic potential
in humans or non-human primates, genomic sequencing indicates
relatively high divergence between Ebola viruses, with nucleotide
differences ranging from 30–45% between species [16].
The role of antibody response in viral clearance and protective
immunity against Ebola viruses in humans is not fully understood,
however samples from individuals with acute ZEBOV infection
have demonstrated antibodies titers that peak relatively early
among those who survive, whereas low or absent antibody titers
are commonly present in those with a fatal outcome [17,18].
Similarly, others have reported the presence of detectable anti-
EBOV antibodies in humans during acute EHF (in some instances
with concurrent detectable viremia [16,19,20]), as well as in
asymptomatic individuals shortly after exposure [21,22], again
suggesting that antibody response may be a correlate of protective
immunity to EHF.
EHF outbreaks commonly occur in remote locations, and often
there is a significant lag between the occurrence of initial illnesses
and subsequent diagnostic sample collection. As a result,
diagnostic samples are frequently collected from individuals
following clearance of viremia, only allowing serologic diagnosis
of EHF. Adding to the challenge in EHF diagnosis, is the near
geographic overlap of at least three pathogenic EBOV species
(ZEBOV, SEBOV, and BEBOV) in central Africa [23,24]. While
we previously have had success in the serologic diagnosis of EBOV
infection using heterologous antigen (for instance, BEBOV was
initially identified by IgM reactivity to ZEBOV antigen [16]), the
overall genetic divergence between EBOV species remains a
concern, and previous data has suggested potential differences in
serologic reactivity to different EBOV species in humans with
EHF [25,26]. In order to examine the extent of serologic cross-
reactivity of EBOV, as well as assess the utility of heterologous
www.plosntds.org 1 June 2011 | Volume 5 | Issue 6 | e1175viral antigen for diagnosis of EBOV infection, we generated non-
recombinant, infectious virus-based antigen preparations for the
five known EBOV species, and examined the IgM and IgG
responses against all five viruses in human sera collected from
previous outbreak responses, associated with ZEBOV, SEBOV,
BEBOV, and REBOV.
Methods
Ethics Statement
All samples were collected as part of public health diagnostic
activities, were pre-existing relative to the start of the study, and
were examined as anonymous samples. Ethical review of the study
protocol was performed by the CDC Investigational Review
Board and study approval was obtained following review, from the
CDC Human Research Protection Office.
Sample selection
Samples for this current study were previously collected as part
of EHF outbreak responses, for 24 individuals infected with
ZEBOV (Kikwit, Democratic Republic of Congo, 1995 [5]), 20
individuals infected with SEBOV (Gulu, Uganda, 2000 [19]), and
33 individuals infected with BEBOV (Bundibugyo, Uganda, 2007
[9]) (table 1). In addition, we assessed antibody responses in 18
samples that were collected from humans in the Philippines and
sent to CDC for confirmatory testing, following the 2008 detection
of REBOV in swine [13]. During diagnostic testing at CDC, the
Philippines samples were found positive for REBOV-reactive IgG
antibodies; the date of onset, or even previous occurrence of illness
in individuals from whom these samples were obtained is
unknown. While the time of sample collection, relative to disease
onset differed between outbreaks (with samples from Gulu tending
to be from earlier stages post-infection than samples from
Bundibugyo or Kikwit), all samples were from individuals who
survived EBOV infection, and diagnostic testing at the time of
outbreak response demonstrated the absence of viremia (by PCR
or antigen detection ELISA) and the presence of IgG antibodies in
each the samples included in this study. Each sample included in
this study is from a discrete individual.
Serology
Antigen preparations for IgM and IgG assays were
performed as described previously [17,27]. Briefly, viral
antigens for IgM and IgG ELISA were prepared by viral
culture in Vero E6 cells, and harvested when at least 90% of
cells had evidence of infection by immunofluorescence assay.
Infected cells were processed by lysis of cells and supernatant
for slurry antigen preparations (IgM) or by detergent basic
buffer extraction of infected cells for lysate antigen prepara-
tions (IgG), as described previously [17,27]. While the
approach for antigen preparation does differ in terms of
antigen concentration between IgM and IgG assays, the viral
antigenic components are similar between both approaches.
The decision to use these specific approaches is based on
previously optimized protocols, which have been applied in
numerous diagnostic settings. Viral antigen preparations were
developed for each of the five known EBOV species, using viral
isolates the following outbreaks: Kikwit, Democratic Republic
of Congo, 1995 (ZEBOV) [5], Gulu, Uganda, 2000 (SEBOV)
[19], Bundibugyo, Uganda, 2007 (BEBOV) [9], the Philippines
(isolate from swine tissue sample submitted to USDA), 2008
(REBOV) [13], and Tai Forest, Co ˆte d’Ivoire, 1994 (CIEBOV)
[6]. Mock-infected control antigens for IgM and IgG assays
were prepared in similar manners, respectively, in the absence
of virus.
Western blots on viral antigen preparations were performed as
described previously [28], individually using hyperimmune mouse
ascitic fluid (HMAF) poly-clonal antibodies [29] against ZEBOV,
SEBOV, REBOV, and CIEBOV, and rabbit poly-clonal
antibodies against ZEBOV, SEBOV, and REBOV, for detection
of EBOV proteins; secondary antibodies were goat anti-mouse
IgG horseradish peroxidase conjugate and goat anti-rabbit IgG
horseradish peroxidase conjugate, respectively.
IgM capture and IgG ELISAs were performed using Clinical
Laboratory Improvement Amendments (CLIA) certified protocols
that have been used for diagnostic testing of EBOV since 1990
[17,27]. For IgM assay, we used goat anti-human IgM antibody
(1:500) for antigen capture, slurry antigen preparations (1:1000),
an HMAF poly-clonal antibody mixture, raised against ZEBOV,
Author Summary
Ebola virus (EBOV) is a highly pathogenic virus, capable of
causing Ebola hemorrhagic fever in humans and non-
human primates. Five species of EBOV have been
identified. To examine whether infection with one EBOV
species results in antibodies that cross-react with other
EBOV species, we selected groups of human diagnostic
samples from four outbreaks, which were each due to a
different EBOV species, and compared IgM and IgG
responses by ELISA to each of the five EBOV species. For
samples from an individual outbreak, we found limited IgM
reactivity to species of EBOV other than the virus species
the individual was infected with. In contrast, for all groups
of outbreak samples we observed strong cross-reactive IgG
antibodies to all EBOV species. Our study demonstrates
that IgG antibody responses tend to be more cross-
reactive than IgM antibody responses in people infected
with EBOV, a finding that has implications for the
development of diagnostic assays and vaccines to EBOV.
Table 1. Summary information on study samples.
Outbreak, year
EBOV species
responsible
for outbreak
Number of samples
included in
current study
Median (days) time
of sample collection,
post-symptom onset
Range (days) of
samples collected,
post-symptom onset
Kitwit, DRC, 1995 ZEBOV 24 73.5 34–116
Gulu, Uganda, 2000 SEBOV 20 18 14–70
Bundibugyo, Uganda, 2007 BEBOV 33 48 33–117
Philippines, 2008 REBOV 18 Unknown Unknown
doi:10.1371/journal.pntd.0001175.t001
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and anti-mouse IgG horseradish peroxidase conjugate (1:8000)
and ABTS substrate. For IgG assay, we used lysate antigen
preparations (1:1000) and mouse anti-human IgG horseradish
peroxidase conjugate (1:4000) and ABTS substrate. ELISAs were
performed for samples, using both viral antigen and mock-infected
antigen, at dilutions of 1:100, 1:400, 1:1600, and 1:6400. Adjusted
optical density (OD) values represent the OD value (at 410 nm) of
an individual sample dilution, after subtracting the OD value of
mock infected antigen from the viral antigen for that dilution. The
adjusted sum OD represents the sum of adjusted OD values of the
four dilutions for an individual sample. For diagnostic assessment
of antibody responses, individual sample dilutions with an adjusted
OD of $0.1 (IgM ELISA) or $0.20 (IgG ELISA) were considered
positive at that respective dilution, and an antibody response was
considered positive for a sample if the sample had a positive titer of
at least 1:400 plus an adjusted sum OD of $0.45 (IgM ELISA) or
$0.95 (IgG ELISA). Cut-off values for the adjusted OD and
adjusted sum OD for both assays correspond with diagnostic
criteria currently used for EHF rule-out testing by CDC, and are
based on previous evaluation of the distribution of values from
thousands of negative serologic samples.
Data analysis
For statistical comparison of adjusted sum OD values between
autologous (reaction to the same EBOV species that the
individual was infected with) and heterologous (reaction to
different EBOV species that the individual was infected with)
virus antigen preparations, we selected all samples from a single
outbreak and performed Wilcoxon rank sum tests, for a non-
parametric paired sample comparison of adjusted sum OD
values. That is, for an individual outbreak, for each sample we
calculated the difference in adjusted sum OD values between
autologous antigen and a single heterologous antigen and tested
whether the distribution of differences for all samples for that
autologous-heterologous antigen pair was different from zero, by
Wilcoxon rank sum test.
Results
We produced non-recombinant infectious virus-based slurry (for
IgM) and lysate (for IgG) antigen preparations for each of the five
EBOV species. In order to confirm the presence of EBOV antigen
in each viral lysate and slurry antigen preparations, we performed
Western blots, using HMAF poly-clonal antibodies, raised against
ZEBOV, SEBOV, REBOV, and CIEBOV (figure 1A) and rabbit
poly-clonal antibodies, raised against ZEBOV, SEBOV, and
REBOV (figure 1B), as detector antibodies. Although neither
detector antibody mixture contained antibodies specifically raised
against BEBOV, the presence of reactive nucleoprotein (NP)
bands near the 100 kilodalton weight marker, both in the lysate
and slurry preparations, indicates the presence of viral antigen in
both of the preparations. While only a faint NP band was detected
in the SEBOV lysate preparation using the HMAF detector
antibody mixture, the presence of antigen was apparent using the
rabbit polyclonal antibody mixture. This may suggest an issue in
reactivity of the HMAF antibody mixture against the SEBOV
lysate preparation. However, we noted the presence of a strong NP
band in the SEBOV slurry preparation, using the HMAF antibody
mixture, indicating the utility of the HMAF as a detector antibody
for the SEBOV IgM ELISA assay.
Samples for this study are convalescent specimens collected as
part of diagnostic activities for outbreaks due to ZEBOV (Kikwit,
Democratic Republic of Congo, 1995 [5]), SEBOV (Gulu,
Uganda, 2000 [19]), BEBOV (Bundibugyo, Uganda, 2007 [9]),
and REBOV (Philippines [13]) (table 1). We quantitatively
examined the IgM antibody reactivity to autologous versus
heterologous virus antigen by comparing adjusted sum OD values
for each of the individual virus slurry antigen preparations, among
outbreak samples. While many of the samples, particularly from
Kikwit and Bundibugyo, had low IgM titers, overall adjusted sum
OD IgM values tended to be higher to autologous than
heterologous virus antigen preparations (figure 2). For instance,
adjusted sum OD values for samples from the Kikwit outbreak
were significantly higher against ZEBOV antigen, than against
SEBOV, BEBOV, and REBOV. Similar trends are also apparent
Figure 1. Western blots showing lysate and slurry antigen preparations for each EBOV species. HMAF poly-clonal antibodies against
ZEBOV, SEBOV, REBOV, and CIEBOV (A) and rabbit poly-clonal antibodies against ZEBOV, SEBOV, and REBOV (B), were used as detector antibodies.
doi:10.1371/journal.pntd.0001175.g001
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ingly we note that samples from the Kikwit outbreak had
significantly higher adjusted sum OD values against CIEBOV
than against ZEBOV, and additionally samples from Bundibugyo
had higher (although not significantly different) values against
CIEBOV than BEBOV antigen. All samples from the Philippines
were demonstrated to be IgM negative during diagnostic testing
and thus adjusted sum OD values were not examined in this study.
We additionally examined IgG antibody reactivity of autologous
versus heterologous virus antigen by comparing adjusted sum OD
values for each of the individual virus lysate antigen preparations
among samples collected from each of the outbreaks. Owing to the
convalescent stage at which most samples were collected, overall
IgG adjusted sum OD values were mostly higher than IgM values
(figure 3). Similar to trends observed for IgM responses, samples
collected from Gulu and Bundibugyo outbreaks had significantly
higher adjusted sum OD IgG values against autologous antigen
than against heterologous antigen (with the exception of samples
from Bundibugyo having higher values against CIEBOV than
against BEBOV). In contrast, adjusted sum OD values for samples
from Kikwit did not differ between ZEBOV and SEBOV,
BEBOV, or REBOV, and had higher values for CIEBOV in
comparison to ZEBOV antigen. Interestingly, samples from the
Philippines had higher adjusted sum OD values against ZEBOV,
SEBOV, and CIEBOV, than against autologous REBOV antigen.
We examined the kinetics of antibody development, for samples
from Kikwit, Gulu, and Bundibugyo, by plotting the adjusted sum
OD to autologous antigen for each of the sets of samples, relative to
time post symptom onset (figure 4). The combined data for samples
from these three outbreaks indicated early presence of IgM antibodies
(earliest samples for this study were at 14 days post symptom onset).
While sample collection dates varied for the Kikwit, Gulu, and
Bundibugyo samples, adjusted sum OD values peaked between 30–
50 days, and largely declined by 80 days post symptom onset. As with
IgM, IgG antibodies were present, even in most early samples,
however, adjusted sum OD values remained high over the full course
(as long as 117 days) of sample collection post-symptom onset.
While the adjusted sum OD measure allowed us to quantitatively
compare serologic cross-reactivity between autologous and heter-
ologous antigens using a continous variable measure, we addition-
ally wanted to examine the performance of heterologous antigen
from a discrete (positive or negative) diagnostic standpoint. In order
to assess the utility of heterologous antigen for the serologic
diagnosis of EBOV infection by IgM ELISA, we selected all
Figure 2. IgM adjusted sum OD values for outbreak samples to each of the five EBOV antigens. Panels represent samples from Kikwit (A),
Gulu (B), and Bundibugyo (C). Closed circles correspond to the adjusted sum OD value for an individual sample to the specific EBOV antigen. Dotted
lines are provided to notate the value of an individual sample across all antigens. Footnote: *Adjusted sum OD value is significantly higher to
heterologous antigen than to autologous antigen.
doi:10.1371/journal.pntd.0001175.g002
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autologous antigen from Kikwit, Gulu, and Bundibugyo outbreaks,
and examined the sensitivity of the heterologous antigens for
serologic diagnosis of EBOV in these samples (table 2). While the
overall sensitivity of heterologous pairs varied widely, many
heterologous virus combinations had low sensitivity for detection
ofpositiveIgMantibodyresponses.Forinstance,SEBOV,BEBOV,
and REBOV antigenpreparations had a sensitivity of less than 40%
for all combinations of heterologous outbreak samples.
We similarly examined the diagnostic utility of heterologous
antigen for the serologic diagnosis of EBOV infection by IgG ELISA.
In contrast to the above results for the IgM assay, heterologous
antigens had a high sensitivity in the detection of IgG antibodies
(table3). With the exception of samples from Gulu, which displayed a
diagnostic sensitivity of 74% with ZEBOV and REBOV antigen, all
heterologous antigen pairs displayed at least 95% sensitivity for
detection of IgG antibodies, and for many combinations, heterolo-
gous antigen detected positive results for 100% of samples.
Discussion
The precise nature of antibody cross-reactivity between EBOV
species has not been fully characterized. Some studies have
reported detectable antibody reactivity to heterologous antigen in
serum from humans or animals [25,27,30,31,32], as well as noted
potential differences in the cross-reactivity between autologous and
heterologous antigen [27,32,33]. However, interpretation of these
results remains difficult, owing the differences in antigen (whole
virus versus recombinant antigen) and overall sample size, for
many previous studies. In this study, among samples from the
Kikwit, Gulu, and Bundibugyo outbreaks, we consistently
observed higher adjusted sum OD values for IgM antibody
responses against autologous antigen than against heterologous
antigens. While IgM antibody responses were low for many
samples (in contrast to IgG responses), when we limited our
analysis to those samples that were positive to autologous antigen
on the basis of diagnostic IgM criteria, we observed low sensitivity
of the IgM ELISA to heterologous antigen. Although some
samples did react to heterologous antigen, our data indicate a
species-specificity of IgM antibody responses in individuals
infected with EBOV.
In contrast to IgM antibody responses, IgG antibodies
consistently displayed cross-reactivity to heterologous antigen, as
demonstrated by the high adjusted sum OD values to heterologous
antigens, as well as the high sensitivity of the IgG ELISA as a
diagnostic assay. Previous serosurveys in Gabon, Central Africa
Figure 3. IgG adjusted sum OD values for outbreak samples to each of the five EBOV antigens. Panels represent samples from Kikwit (A),
Gulu (B), Bundibugyo (C), and Philippines (D). Closed circles correspond to the adjusted sum OD value for an individual sample to the specific EBOV
antigen. Dotted lines are provided to notate the value of an individual sample across all antigens. Footnote: *Adjusted sum OD value is significantly
higher to heterologous antigen than to autologous antigen.
doi:10.1371/journal.pntd.0001175.g003
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correspond to IgM (A) and IgG (B) assays.
doi:10.1371/journal.pntd.0001175.g004
Table 2. Sensitivity of IgM ELISA, using heterologous antigen.
Outbreak
(virus)
# Positive with
autologous virus
# Positive, ZEBOV
antigen (Sensitivity)
# Positive, SEBOV
Antigen (Sensitivity)
# Positive, BEBOV
Antigen (Sensitivity)
# Positive, REBOV
Antigen (Sensitivity)
# Positive, CIEBOV
Antigen (Sensitivity)
Kitwit (ZEBOV) 8 0 (0%) 1 (13%) 3 (38%) 6 (75%)
Gulu (SEBOV) 16 10 (67%) 2 (13%) 0 (0%) 7 (47%)
Bundibugyo
(BEBOV)
15 8 (53%) 5 (34%) 2 (13%) 13 (87%)
doi:10.1371/journal.pntd.0001175.t002
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prevalence of anti-EBOV antibodies in rural populations ranging
from (5–15%), which were presumed as indicative of previous
infection with ZEBOV [34,35,36]. Owing to the high degree of
IgG cross-reactivity we observed in this study, it is possible the
relatively high seroprevalence of anti-EBOV antibodies reported
in these studies may be the result of exposure to an unknown
EBOV species, with lower pathogen potential than ZEBOV.
The kinetics of antibody response to EBOV in humans has been
best described for ZEBOV. Ksiazek et al reported early onset and
peaking (,18 days) of IgM responses, which largely diminished by
60 days post-infection, while IgG antibodies were also present
early post-onset and persisted for months following infection, in
survivors [17]. Similar observations were reported by Baize et al.
[18] and recent data from Wauquier et al. indicated that ZEBOV-
reactive IgG antibodies persist for years following EHF [37]. While
the samples examined in this study are not uniform with regard to
time post-symptom onset, relative the EHF outbreak, our data do
suggest the above observations can be extended for other EBOV
species.
An unexpected finding in this study was the overall high level of
seroreactivity of heterologous samples to CIEBOV antigen. For
instance, IgM adjusted sum OD values for samples from Kikwit,
and IgG adjusted sum OD values from Kikwit, Bundibugyo, and
the Philippines, were all significantly higher for heterologous
CIEBOV antigen than for autologous antigen. The reason for this
observation is unclear, however these are likely not the result of
higher concentrations of CIEBOV antigen in lysate and slurry
preparations, as demonstrated by the similar antigen concentra-
tion of CIEBOV antigen to the other antigen preparations in
Western blot. It would be of interest to compare the cross-
reactivity of human anti-CIEBOV sera, between autologous and
heterologous EBOV antigen, however because of the scarcity of
identified human infections (only one patient diagnosed) with to
CIEBOV, we were unable to address this question.
In addition, for samples from the Philippines, adjusted sum OD
values for IgG tended to be higher against heterologous antigens
than again REBOV antigen. We do not have an explanation for
this observation, however, owing to the absence of detectable IgM
responses in any samples from the Philippines, and the apparent
lack of symptomatic disease in humans exposed to REBOV, these
samples could represent later stage serologic responses in
comparison to the other groups of samples, and may potentially
include individuals with boosted immune responses due to
multiple previous exposures to REBOV.
Our observations indicate limitations in the utility of IgM
ELISA, for diagnosis of EHF, prior to identification of the virus
species. However, previous studies have reported early develop-
ment of IgG antibodies in surviving EHF cases [17,18] (and
similarly supported by temporal data from this study). Because the
IgG ELISA detected positive IgG antibody responses for the
majority of samples with heterologous antigen, IgG ELISA assays
in late-acute or early-convalescent samples may effectively
circumvent the limitations in IgM ELISA, for diagnosis of EHF
when the viral species is not known.
We do note limitations of our study. The limited availability of
diagnostic sera prohibited the opportunity to examine antibody
cross-reactivity to specific EBOV proteins, or to specific epitopes.
While the antigenic preparations used for ELISA in our study may
be modestly enriched for NP, this approach does not preclude
other proteins (as demonstrated by Western blot in figure 1) and
antigen preparations were used at high concentrations for the
ELISAs [17,27]. For instance, in a recent study, Becquart et al.
used the same IgG ELISA (including ZEBOV antigen produced in
the same manner) as this current study to identify a large number
of seropositive individuals, and confirmed EBOV-specific antibody
responses in 138 individuals by Western blot. All individuals
reacted to at least one viral protein, however, only 56% displayed
antibody reactivity to NP [36].
Secondly, while we quantified IgM and IgG antibody levels,
these do not necessarily represent the presence or quantity of
neutralizing antibodies. The kinetics of development and func-
tional role of neutralizing antibodies in viral clearance and
protection in humans in not well understood. Currently most
known neutralizing antibodies to EBOV target epitopes in the
viral glycoprotein (GP), and data suggest GP as an important
protein for viral neutralization [38,39,40,41,42]. Interestingly, in
studies involving humans with evidence of asymptomatic infection
[22] and humans seropositive to EBOV [36], the most common
seroreactive proteins by Western blot were VP40 and NP; only a
minority of individuals displayed evidence of reactive antibodies to
GP. Although it is possible that antibody responses have a limited
role in protective immunity to EBOV in humans, data from these
studies (living individuals with evidence of previous EBOV
infection) as well as from outbreak studies [17,18], support the
notion that antibody responses are an important correlate of
immunity to EBOV in humans.
In summary, we assessed the cross-reactive nature of IgM and
IgG antibodies from groups of human survivors who were infected
with four different species of EBOV. We observed cross-reactivity
of IgG antibodies to heterologous antigen, however, overall
reactivity to IgM and IgG antibodies tended to be stronger for
autologous than heterologous antigen. Some experimental vac-
cines have suggested limited cross-protection of heterologous
EBOV antigen [43]. Hensley et al. recently reported cross-
protection against BEBOV infection in cynomolgus macaques
vaccinated with DNA/rAd5 vaccine expressing GP of ZEBOV
and SEBOV, although concluded that protection was the result of
Table 3. Sensitivity of IgG ELISA, using heterologous antigen.
Outbreak
(virus)
# Positive with
autologous virus
# Positive, ZEBOV
antigen (Sensitivity)
# Positive, SEBOV
Antigen (Sensitivity)
# Positive, BEBOV
Antigen (Sensitivity)
# Positive, REBOV
Antigen (Sensitivity)
# Positive, CIEBOV
Antigen (Sensitivity)
Kitwit (ZEBOV) 24 24 (100%) 24 (100%) 24 (100%) 24 (100%)
Gulu (SEBOV) 19 14 (74%) 18 (95%) 14 (74%) 18 (95%)
Bundibugyo
(BEBOV)
33 33 (100%) 33 (100%) 33 (100%) 33 (100%)
Philippines
(REBOV)
18 18 (100%) 18 (100%) 18 (100%) 18 (100%)
doi:10.1371/journal.pntd.0001175.t003
Cross-Reactivity of Human Sera to Ebola Virus
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heterologous vaccine for protection against EBOV, should IgG
antibody responses prove to be an effective mediator of immunity
to EBOV in humans.
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